ANR-001.1 (latanoprost + minoxidil)
ANR-001.1 (latanoprost + minoxidil) is in Phase 1 for androgenetic alopecia, developed by Aneira Pharma.
A fixed combination of latanoprost and minoxidil, with a Phase 1 in men and an eyebrow pilot registered and neither updated since 2023.
- Developed by
- Aneira Pharma
- Current phase
- Phase 1
- Mechanism
- Combination
- Indications
- Androgenetic alopecia, Female pattern hair loss
- Also known as
- ANR-001, ANR-001.1, ANR001
- Last public activity
- No trials on record
- Copy last reviewed
- September 2026
- Record confidence
- Low
First tests in humans. Answers 'is it safe?', not 'does it work?'.
Combines two or more mechanisms in one product.
A research record, not medical advice: being listed here says nothing about whether a treatment works or whether it is right for you. Talk to a dermatologist about your own case.
Why it matters
Two molecules with a hair record, combined: minoxidil is approved for hair loss, latanoprost is a glaucoma drug studied on eyelashes and eyebrows. That lowers the scientific risk and raises the regulatory bar, since in the US a fixed-dose combination has to show each component contributes, not merely that it beats placebo. Aneira registered a 14-man Phase 1 pharmacokinetic study and an eyebrow proof-of-concept in 2023; both carry status 'unknown'. The row rests on those records and the company's own description, and is marked LOW accordingly.
Development history
No phase changes recorded yet.
Registered trials
Pulled automatically from ClinicalTrials.gov. Matching is by name and development code, so occasional gaps are possible — tell us if you spot one.
No trials matched to this programme in ClinicalTrials.gov.
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first.
Sources
- Aneira Pharma — pipeline — Company release
- Once-Daily Topical Solution (ANR-001.1) in Male Subjects With Androgenetic Alopecia, Phase 1 pharmacokinetics — ClinicalTrials.gov
- Proof of Concept of Latanoprost/Minoxidil (ANR-001.1) Topical Formulation for Eyebrows — ClinicalTrials.gov
- 21 CFR 300.50, fixed-combination prescription drugs for humans — Regulator filing
Related programmes
Other programmes in the register with the same mechanism: Combination.
Cite this page
Hair Pipeline, "ANR-001.1 (latanoprost + minoxidil) — development record", hairpipeline.com/pipeline/anr-001